Halozyme Therapeutics (HALO) Current Deferred Revenue (2010 - 2023)
Halozyme Therapeutics (HALO) posted quarterly Current Deferred Revenue of $667000.0 for Q3 2023, down 81.4% year-over-year from $3.6 million in Q3 2022, and down 78.45% quarter-over-quarter from $3.1 million in Q2 2023.
Halozyme Therapeutics (HALO) Current Deferred Revenue (2010 - 2023) Analysis & Trends
Halozyme Therapeutics (HALO) has reported Current Deferred Revenue for 14 consecutive years, with $667000.0 the latest figure, recorded in Q3 2023.
- In Q3 2023, Current Deferred Revenue fell 81.4% year-over-year to $667000.0; the TTM figure through Sep 2023 stood at $667000.0 (down 81.4% YoY), while the FY2022 annual figure was $3.2 million, down 24.09% from the prior year.
- Current Deferred Revenue eased to $667000.0 in Q3 2023 per HALO's latest filing, from $3.1 million in the prior quarter.
- Across five years, Current Deferred Revenue topped out at $6.9 million in Q2 2022 and bottomed at $667000.0 in Q3 2023.
- Historically, Current Deferred Revenue has averaged $3.6 million across 5 years, with a median of $3.8 million in 2022.
- Annual changes were most pronounced in 2019 — Current Deferred Revenue plunged 92.25% — and 2021, when it jumped 604.95%.
- Halozyme Therapeutics' Current Deferred Revenue stood at $4.0 million in 2019, then sank by 56.48% to $1.7 million in 2020, then surged by 144.9% to $4.3 million in 2021, then declined by 24.09% to $3.2 million in 2022, then slumped by 79.45% to $667000.0 in 2023.
- Business Quant data shows HALO's Current Deferred Revenue at $667000.0 in Q3 2023, $3.1 million in Q2 2023, and $5.5 million in Q1 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Halozyme Therapeutics | 11.25 Bn | 11.02 Bn | 401.83 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2023 | 667,000.00 |
| Jun 30, 2023 | 3.10 Mn |
| Mar 31, 2023 | 5.50 Mn |
| Dec 31, 2022 | 3.25 Mn |
| Sep 30, 2022 | 3.59 Mn |
| Jun 30, 2022 | 6.87 Mn |
| Mar 31, 2022 | 3.78 Mn |
| Dec 31, 2021 | 4.28 Mn |
| Sep 30, 2021 | 4.78 Mn |
| Jun 30, 2021 | 5.27 Mn |
| Mar 31, 2021 | 1.75 Mn |
| Dec 31, 2020 | 1.75 Mn |
| Sep 30, 2020 | 748,000.00 |
| Jun 30, 2020 | 748,000.00 |
| Mar 31, 2020 | 4.65 Mn |
| Dec 31, 2019 | 4.01 Mn |
| Sep 30, 2019 | 3.51 Mn |
| Jun 30, 2019 | 6.51 Mn |
| Mar 31, 2019 | 4.25 Mn |
| Dec 31, 2018 | 51.80 Mn |